股本结构
单位：万股
| 公告日期 | 2025-10-29 | 2025-10-20 | 2025-10-20 | 2025-08-11 | 2025-08-11 | 2025-05-01 |
|---|---|---|---|---|---|---|
| 证券总股本 | 77115.04 | 74444.25 | 74444.25 | 74284.67 | 74280.67 | 74266.59 |
| 普通股本 | 77115.04 | 74444.25 | 74444.25 | 74284.67 | 74280.67 | 74266.59 |
| 优先股 | 未披露 | 未披露 | 未披露 | 未披露 | 未披露 | 未披露 |
| 其他 | 未披露 | 未披露 | 未披露 | 未披露 | 未披露 | 未披露 |
| 变动日期 | 2025-10-24 | 2025-10-14 | 2025-09-30 | 2025-08-05 | 2025-06-30 | 2025-04-25 |
注释：中概股证券总股本=普通股股本/
存托凭证比例
，当前存托凭证比例为：1
历史变动
| 公告日期 | 变动后普通股本（万股） | 变动后优先股（万股） | 变动原因 | 变动日期 |
|---|---|---|---|---|
| 2025-10-29 | 77115.04 | 未披露 | 定期报告 | 2025-10-24 |
| 2025-10-20 | 74444.25 | 未披露 | 定期报告 | 2025-10-14 |
| 2025-10-20 | 74444.25 | 未披露 |
更多>>
From June 30, 2025 to September 30, 2025
Issuance of common stock under stock purchase plans and exercise of stock options
Proceeds from at-the-market offering, net of commissions and fees of $794
|
2025-09-30 |
| 2025-08-11 | 74284.67 | 未披露 | 定期报告 | 2025-08-05 |
| 2025-08-11 | 74280.67 | 未披露 |
更多>>
From March 31, 2025 to June 30, 2025
Issuance of common stock upon exercise of stock options and warrants
|
2025-06-30 |
| 2025-05-01 | 74266.59 | 未披露 | 定期报告 | 2025-04-25 |
| 2025-04-29 | 74266.07 | 未披露 | 定期报告 | 2025-04-15 |
| 2025-05-01 | 74160.94 | 未披露 |
更多>>
From December 31, 2024 to March 31, 2025
Issuance of common stock under stock purchase plans and exercise of stock options and warrants
|
2025-03-31 |
| 2025-02-24 | 73767.97 | 未披露 | 定期报告 | 2025-02-18 |
| 2025-02-24 | 73762.60 | 未披露 |
更多>>
From December 31, 2023 to December 31, 2024
Private placement of common stock, net of offering costs of $140
Issuance of common stock under stock purchase plans and exercise of stock options and warrants
Proceeds from at-the-market offering, net of commissions and offering costs of $1,190
|
2024-12-31 |
| 2024-10-30 | 73744.81 | 未披露 | 定期报告 | 2024-10-23 |
| 2024-10-30 | 73709.50 | 未披露 |
更多>>
From June 30, 2024 to September 30, 2024
Private placement of common stock, net of offering costs of $140
Issuance of common stock under stock purchase plans and exercise of stock options and warrants
Proceeds from at-the-market offering, net of commissions and offering costs of $1190
|
2024-09-30 |
| 2024-09-13 | 73516.04 | 未披露 | 定期报告 | 2024-09-13 |
| 2024-08-06 | 72453.78 | 未披露 | 定期报告 | 2024-07-30 |
| 2024-08-06 | 72432.02 | 未披露 |
更多>>
From March 31, 2024 to June 30, 2024
Private placement of common stock
Issuance of common stock under stock purchase plans and exercise of stock options and warrants
|
2024-06-30 |
| 2024-05-01 | 70197.96 | 未披露 | 定期报告 | 2024-04-22 |
| 2024-05-01 | 70197.46 | 未披露 |
更多>>
From December 31, 2023 to March 31, 2024
Issuance of common stock under stock purchase plans and exercise of stock options
|
2024-03-31 |
| 2024-02-20 | 70170.34 | 未披露 | 定期报告 | 2024-02-13 |
| 2024-02-20 | 70169.72 | 未披露 | 定期报告 | 2024-02-09 |
| 2024-02-20 | 70166.01 | 未披露 |
更多>>
From December 31, 2022 to December 31, 2023
Issuance of common stock under employee stock purchase plans and exercise of stock options
Issuance of common stock in lieu of cash for Akeso upfront payment
Private placement of common stock
Exercise of warrants
|
2023-12-31 |
| 2023-11-07 | 70084.29 | 未披露 | 定期报告 | 2023-10-31 |
| 2023-11-07 | 69785.13 | 未披露 |
更多>>
From June 30, 2023 to September 30, 2023
Issuance of common stock under stock purchase plans and exercise of stock options
|
2023-09-30 |
| 2023-09-19 | 69785.13 | 未披露 | 定期报告 | 2023-09-18 |
| 2023-05-11 | 69768.54 | 未披露 |
更多>>
From December 31, 2022 to March 31, 2023
Issuance of common stock in lieu of cash for Akeso upfront payment
Rights offering of common stock, net of offering costs of $619
Issuance of common stock under stock purchase plans and exercise of stock options
|
2023-03-31 |
| 2023-03-09 | 69768.54 | 未披露 | 定期报告 | 2023-03-07 |
| 2023-03-03 | 69770.00 | 未披露 |
更多>>
On March 3, 2023, Summit Therapeutics Inc. (the “Company”) issued a press release announcing the closing and final results of its previously announced rights offering. The offering, which was fully subscribed, resulted in the issuance of approximately 476.2 million shares of common stock, par value $0.01 per share (“Common Stock”), at a price of $1.05 per share. Aggregate gross proceeds from the rights offering were $500 million. After giving effect to the issuance of approximately 476.2 million shares of common stock in the rights offering, the Company has approximately 697.7 million shares of Common Stock issued and outstanding.
|
2023-03-03 |
| 2023-02-07 | 22124.17 | 未披露 | 定期报告 | 2023-02-06 |
| 2023-03-09 | 21109.14 | 未披露 |
更多>>
From December 31, 2021 to December 31, 2022
2022 Rights Offering of common stock, net of offering costs of $111
Issuance of common stock in lieu of interest to related parties
Issuance of common stock under stock purchase plans and exercise of stock options
|
2022-12-31 |
| 2022-11-09 | 20132.12 | 未披露 |
更多>>
From June 30, 2022 to September 30, 2022
Rights offering of common stock, net of offering costs of $111
Issuance of common stock under stock purchase plans and exercise of stock options
|
2022-09-30 |
| 2022-08-09 | 20100.00 | 未披露 |
更多>>
After giving effect to the issuance of approximately 103 million shares of common stock in the rights offering, the Company has approximately 201 million shares of Common Stock issued and outstanding.
|
2022-08-09 |
| 2022-08-11 | 9812.24 | 未披露 | 定期报告 | 2022-06-30 |
| 2022-03-17 | 9812.24 | 未披露 | 定期报告 | 2022-03-10 |
| 2022-03-17 | 9803.95 | 未披露 |
更多>>
From December 31, 2020 to December 31, 2021
Rights offering of common stock, net of offering costs of $159
Issuance of common stock from exercise of stock options
|
2021-12-31 |
| 2021-11-15 | 9771.44 | 未披露 | 定期报告 | 2021-11-08 |
| 2021-11-15 | 9762.85 | 未披露 |
更多>>
From June 30, 2021 to September 30, 2021
Issuance of common stock from exercise of stock options
|
2021-09-30 |
| 2021-08-12 | 9738.18 | 未披露 | 定期报告 | 2021-08-05 |
| 2021-08-12 | 9735.18 | 未披露 |
更多>>
From March 31, 2021 to June 30, 2021
Rights offering of common stock, net of offering costs of $118
Issuance of common stock from exercise of stock options
|
2021-06-30 |
| 2021-05-17 | 9724.46 | 未披露 | 定期报告 | 2021-05-12 |
| 2021-04-21 | 8292.67 | 未披露 | 定期报告 | 2021-04-09 |
| 2021-05-17 | 8291.95 | 未披露 |
更多>>
From December 31, 2020 To March 31, 2021
Issuance of common stock from exercise of stock options
|
2021-03-31 |
| 2021-03-31 | 8291.62 | 未披露 | 定期报告 | 2021-03-24 |
| 2021-01-08 | 8257.51 | 未披露 | 定期报告 | 2020-12-30 |
| 2020-11-16 | 8226.00 | 未披露 | 定期报告 | 2020-11-11 |
| 2020-09-29 | 6723.19 | 未披露 |
更多>>
Our common stock has been publicly traded on the Nasdaq Global Market under the symbol “SMMT” since September 21, 2020. Prior to that date, there was no public market for our common stock. Prior to the closing of the Redomiciliation Transaction, pursuant to which Summit Therapeutics plc became our wholly-owned subsidiary, Summit Therapeutics plc's ADSs had traded on the Nasdaq Global Market under the symbol "SMMT" since March 2015. Each ADS represented five ordinary shares of Summit Therapeutics plc. In the Redomiciliation Transaction, five ordinary shares of Summit Therapeutics plc were exchanged for one share of our common stock.
|
2020-09-21 |
| 2020-04-30 | 33589.03 | 未披露 |
更多>>
from January 31, 2019 to December 31, 2019
New share capital issued (net of transaction costs)
Share options exercised
|
2019-12-31 |
| 2019-06-12 | 16049.48 | 未披露 |
更多>>
from January 31, 2019 to April 30, 2019
Share options exercised
|
2019-04-30 |
| 2019-03-29 | 16038.99 | 未披露 |
更多>>
from January 31, 2018 to January 31, 2019
New share capital issued
Share options exercised
|
2019-01-31 |
| 2018-12-11 | 8226.49 | 未披露 | 定期报告 | 2018-10-31 |
| 2018-09-20 | 8212.60 | 未披露 |
更多>>
from February 1, 2018 to July 31, 2018
New share capital issued
Share options exercised
|
2018-07-31 |
| 2018-06-05 | 8198.90 | 未披露 | 定期报告 | 2018-04-30 |
| 2018-04-13 | 7356.36 | 未披露 |
更多>>
from January 31, 2017 to January 31, 2018
New share capital issued (net of transaction costs)
Issue of Ordinary Shares as consideration for a business combination
New share capital issued from exercise of warrants
Share options exercised
|
2018-01-31 |
| 2017-03-30 | 6184.16 | 未披露 | 定期报告 | 2017-01-31 |
| 2016-09-08 | 6148.45 | 未披露 | 定期报告 | 2016-06-28 |
| 2016-05-10 | 6146.78 | 未披露 | 定期报告 | 2016-04-14 |
| 2015-12-17 | 6129.07 | 未披露 | 定期报告 | 2015-10-31 |
| 2015-06-11 | 6098.26 | 未披露 | 定期报告 | 2015-03-23 |
| 2015-03-05 | 5836.77 | 未披露 | 定期报告 | 2015-03-05 |
| 2015-05-07 | 4111.77 | 未披露 | 定期报告 | 2015-01-31 |
From June 30, 2025 to September 30, 2025
Issuance of common stock under stock purchase plans and exercise of stock options
Proceeds from at-the-market offering, net of commissions and fees of $794
From March 31, 2025 to June 30, 2025
Issuance of common stock upon exercise of stock options and warrants
From December 31, 2024 to March 31, 2025
Issuance of common stock under stock purchase plans and exercise of stock options and warrants
From December 31, 2023 to December 31, 2024
Private placement of common stock, net of offering costs of $140
Issuance of common stock under stock purchase plans and exercise of stock options and warrants
Proceeds from at-the-market offering, net of commissions and offering costs of $1,190
From June 30, 2024 to September 30, 2024
Private placement of common stock, net of offering costs of $140
Issuance of common stock under stock purchase plans and exercise of stock options and warrants
Proceeds from at-the-market offering, net of commissions and offering costs of $1190
From March 31, 2024 to June 30, 2024
Private placement of common stock
Issuance of common stock under stock purchase plans and exercise of stock options and warrants
From December 31, 2023 to March 31, 2024
Issuance of common stock under stock purchase plans and exercise of stock options
From December 31, 2022 to December 31, 2023
Issuance of common stock under employee stock purchase plans and exercise of stock options
Issuance of common stock in lieu of cash for Akeso upfront payment
Private placement of common stock
Exercise of warrants
From June 30, 2023 to September 30, 2023
Issuance of common stock under stock purchase plans and exercise of stock options
From December 31, 2022 to March 31, 2023
Issuance of common stock in lieu of cash for Akeso upfront payment
Rights offering of common stock, net of offering costs of $619
Issuance of common stock under stock purchase plans and exercise of stock options
On March 3, 2023, Summit Therapeutics Inc. (the “Company”) issued a press release announcing the closing and final results of its previously announced rights offering. The offering, which was fully subscribed, resulted in the issuance of approximately 476.2 million shares of common stock, par value $0.01 per share (“Common Stock”), at a price of $1.05 per share. Aggregate gross proceeds from the rights offering were $500 million. After giving effect to the issuance of approximately 476.2 million shares of common stock in the rights offering, the Company has approximately 697.7 million shares of Common Stock issued and outstanding.
From December 31, 2021 to December 31, 2022
2022 Rights Offering of common stock, net of offering costs of $111
Issuance of common stock in lieu of interest to related parties
Issuance of common stock under stock purchase plans and exercise of stock options
From June 30, 2022 to September 30, 2022
Rights offering of common stock, net of offering costs of $111
Issuance of common stock under stock purchase plans and exercise of stock options
After giving effect to the issuance of approximately 103 million shares of common stock in the rights offering, the Company has approximately 201 million shares of Common Stock issued and outstanding.
From December 31, 2020 to December 31, 2021
Rights offering of common stock, net of offering costs of $159
Issuance of common stock from exercise of stock options
From June 30, 2021 to September 30, 2021
Issuance of common stock from exercise of stock options
From March 31, 2021 to June 30, 2021
Rights offering of common stock, net of offering costs of $118
Issuance of common stock from exercise of stock options
From December 31, 2020 To March 31, 2021
Issuance of common stock from exercise of stock options
Our common stock has been publicly traded on the Nasdaq Global Market under the symbol “SMMT” since September 21, 2020. Prior to that date, there was no public market for our common stock. Prior to the closing of the Redomiciliation Transaction, pursuant to which Summit Therapeutics plc became our wholly-owned subsidiary, Summit Therapeutics plc's ADSs had traded on the Nasdaq Global Market under the symbol "SMMT" since March 2015. Each ADS represented five ordinary shares of Summit Therapeutics plc. In the Redomiciliation Transaction, five ordinary shares of Summit Therapeutics plc were exchanged for one share of our common stock.
from January 31, 2019 to December 31, 2019
New share capital issued (net of transaction costs)
Share options exercised
from January 31, 2019 to April 30, 2019
Share options exercised
from January 31, 2018 to January 31, 2019
New share capital issued
Share options exercised
from February 1, 2018 to July 31, 2018
New share capital issued
Share options exercised
from January 31, 2017 to January 31, 2018
New share capital issued (net of transaction costs)
Issue of Ordinary Shares as consideration for a business combination
New share capital issued from exercise of warrants
Share options exercised